Investors Sue Capricor Therapeutics Over Securities Fraud Allegations
A law firm has launched an investigation into Capricor Therapeutics, Inc. regarding alleged securities fraud related to FDA review and an advisory committee meeting.
Glancy Prongay Wolke & Rotter LLP, a national law firm, announced it has begun an investigation on behalf of investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR). The probe centers on allegations of securities fraud concerning the company's dealings with the U.S. Food and Drug Administration (FDA) regarding a product review and an advisory committee meeting.
The investigation stems from claims that Capricor may have issued misleading statements about the clinical trial results for its drug candidate, CAP-1002, and the subsequent FDA approval process. Investors who have experienced financial losses in Capricor stock are urged to contact Glancy Prongay Wolke & Rotter LLP.
Glancy Prongay Wolke & Rotter LLP specializes in shareholder rights litigation and has represented investors in numerous cases across the United States. The firm suggests that shareholders may have been misled by the company's public statements, which could have impacted the stock's valuation.
This investigation could impact Capricor Therapeutics' ongoing FDA approval pathway and its corporate reputation. Investors are advised to be aware of the firm's actions and the potential implications.